The Role of Gut Microbiome in Rheumatoid Arthritis

Exploring the intricate link between intestinal mucosal permeability, dysbiosis, and systemic joint inflammation in early RA. The gut microbiome plays an increasingly recognized role in priming systemic immune responses. In genetically susceptible individuals (HLA-DRB1 allele carriers), intestinal mucosal dysbiosis triggers post-translational modifications such as citrullination. This leads to anti-citrullinated protein antibody (ACPA) generation years before joint symptoms manifest. Key Clinical Takeaways: 1. Early dietary modification rich in short-chain fatty acids (SCFAs) helps stabilize mucosal barriers. 2. Screening for subclinical gut inflammation in ACPA-positive patients provides actionable preventative windows. 3. Combining targeted DMARD therapy with microbiome optimization improves long-term clinical remission rates. Management of chronic autoimmune conditions requires personalized therapeutic drug monitoring (TDM). At RICE, we employ real-time musculoskeletal ultrasound (MSK-US) alongside extended serological testing to ensure patients remain in deep clinical remission with minimal corticosteroid exposure.